Pilot Study of a Raltegravir Based NRTI Sparing Regimen
What is the purpose of this trial?
This pilot study will provide data on the safety and efficacy of the combination of Raltegravir (RAL) 400mg BID + Atazanavir (ATV) 300 mg BID in Antiretroviral (ARV)-experienced subjects that have a suppressed HIV viral load on a Ritonavir (RTV) boosted Protease Inhibitor (PI) based regimen who are then switched to a regimen of RAL 400mg BID +ATV 300mg BID.
- 18 Years and older
- Bristol-Myers Squibb
Merck Sharp & Dohme Corp.
- May 2009
- Last Updated:
- July 15, 2014
- Study HIC#:
Clinicaltrials.gov ID: NCT00814879